9 results on '"Kelsey Ogomori"'
Search Results
2. Acute Effects of Coffee Consumption on Health among Ambulatory Adults
- Author
-
Gregory M. Marcus, David G. Rosenthal, Gregory Nah, Eric Vittinghoff, Christina Fang, Kelsey Ogomori, Sean Joyce, Defne Yilmaz, Vivian Yang, Tara Kessedjian, Emily Wilson, Michelle Yang, Kathleen Chang, Grace Wall, and Jeffrey E. Olgin
- Subjects
General Medicine - Published
- 2023
3. Acute Consumption of Alcohol and Discrete Atrial Fibrillation Events
- Author
-
Christina D. Fang, Randall J. Lee, Rachel A. Gladstone, Kelsey Ogomori, Vivian Yang, Eric Vittinghoff, Byron K. Lee, Gregory M. Marcus, Emily Lee, Gregory Nah, Isaac R. Whitman, Edward P. Gerstenfeld, Shannon M Fan, Vasanth Vedantham, Henry H. Hsia, Jeffrey E. Olgin, Sean Joyce, Zian H. Tseng, Robin Fatch, Joshua D. Moss, Judith A. Hahn, and Melvin M. Scheinman
- Subjects
Male ,medicine.medical_specialty ,Alcohol Drinking ,Population ,Alcohol abuse ,Alcohol ,Odds ,chemistry.chemical_compound ,Internal medicine ,Atrial Fibrillation ,Internal Medicine ,Humans ,Medicine ,Prospective Studies ,education ,education.field_of_study ,Cross-Over Studies ,business.industry ,Area under the curve ,Atrial fibrillation ,General Medicine ,Odds ratio ,Middle Aged ,medicine.disease ,chemistry ,Ambulatory ,Electrocardiography, Ambulatory ,Blood Alcohol Content ,Female ,business - Abstract
BACKGROUND Patients' self-reports suggest that acute alcohol consumption may trigger a discrete atrial fibrillation (AF) event. OBJECTIVE To objectively ascertain whether alcohol consumption heightens risk for an AF episode. DESIGN A prospective, case-crossover analysis. SETTING Ambulatory persons in their natural environments. PARTICIPANTS Consenting patients with paroxysmal AF. MEASUREMENTS Participants were fitted with a continuous electrocardiogram (ECG) monitor and an ankle-worn transdermal ethanol sensor for 4 weeks. Real-time documentation of each alcoholic drink consumed was self-recorded using a button on the ECG recording device. Fingerstick blood tests for phosphatidylethanol (PEth) were used to corroborate ascertainments of drinking events. RESULTS Of 100 participants (mean age, 64 years [SD, 15]; 79% male; 85% White), 56 had at least 1 episode of AF. Results of PEth testing correlated with the number of real-time recorded drinks and with events detected by the transdermal alcohol sensor. An AF episode was associated with 2-fold higher odds of 1 alcoholic drink (odds ratio [OR], 2.02 [95% CI, 1.38 to 3.17]) and greater than 3-fold higher odds of at least 2 drinks (OR, 3.58 [CI, 1.63 to 7.89]) in the preceding 4 hours. Episodes of AF were also associated with higher odds of peak blood alcohol concentration (OR, 1.38 [CI, 1.04 to 1.83] per 0.1% increase in blood alcohol concentration) and the total area under the curve of alcohol exposure (OR, 1.14 [CI, 1.06 to 1.22] per 4.7% increase in alcohol exposure) inferred from the transdermal ethanol sensor in the preceding 12 hours. LIMITATION Confounding by other time-varying exposures that may accompany alcohol consumption cannot be excluded, and the findings from the current study of patients with AF consuming alcohol may not apply to the general population. CONCLUSION Individual AF episodes were associated with higher odds of recent alcohol consumption, providing objective evidence that a modifiable behavior may influence the probability that a discrete AF event will occur. PRIMARY FUNDING SOURCE National Institute on Alcohol Abuse and Alcoholism.
- Published
- 2021
4. YAP facilitates melanoma migration through regulation of actin-related protein 2/3 complex subunit 5 (ARPC5)
- Author
-
Lee Huang, Yan Li, Kelsey Ogomori, Deborah Lang, Stephen P.G. Moore, and Jason W. Lui
- Subjects
Skin Neoplasms ,Protein subunit ,Cell ,Arp2/3 complex ,Dermatology ,General Biochemistry, Genetics and Molecular Biology ,Article ,Actin-Related Protein 2-3 Complex ,Transcriptome ,Focal adhesion ,Cell Movement ,Cell Line, Tumor ,medicine ,Transcriptional regulation ,Cell Adhesion ,Humans ,Neoplasm Invasiveness ,Melanoma ,Matrigel ,Focal Adhesions ,biology ,YAP-Signaling Proteins ,medicine.disease ,Cell biology ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,Oncology ,Transcriptional Coactivator with PDZ-Binding Motif Proteins ,biology.protein ,Signal Transduction - Abstract
Yes Associated Protein 1 (YAP) and Transcriptional coactivator with PDZ-Binding Motif (TAZ) are transcriptional coactivators that have been implicated in driving metastasis and progression in many cancers, mainly through their transcriptional regulation of downstream targets. Although YAP and TAZ have shown redundancy in many contexts, it is still unknown whether or not this is true in melanoma. Here we show that while both YAP and TAZ are expressed in a panel of melanoma cell lines, depletion of YAP results in decreased cell numbers, focal adhesions, and the ability to invade matrigel. Using non-biased RNA-sequencing analysis, we find that melanoma cells depleted of YAP, TAZ, or YAP/TAZ exhibit drastically different transcriptomes. We further uncover the ARP2/3 subunit ARPC5 as a specific target of YAP but not TAZ, and that ARPC5 is essential for YAP-dependent maintenance of melanoma cell focal adhesion numbers. Our findings suggest that in melanoma, YAP drives melanoma progression, survival, and invasion. SIGNIFICANCE: Our findings are the first to differentiate YAP from its ortholog TAZ as a unique driver of melanoma using cell dependency studies, non-biased RNA sequencing, and a downstream target-based approach. Genetic and functional data implicate the actin nucleating ARP2/3 complex in melanoma and we discovered that the ARP2/3 subunit ARPC5 is a downstream target of YAP but not TAZ. ARPC5 acts as a downstream effector factor for YAP in focal adhesion maintenance, likely contributing to melanoma migration and metastasis.
- Published
- 2021
5. B-PO02-152 ELECTROCARDIOGRAPHIC CHANGES IN A DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED TRIAL OF ETHANOL VERSUS PLACEBO
- Author
-
Gregory M. Marcus, Vasanth Vedantham, Vijay A. Ramchandani, Eric Vittinghoff, Nitish Badhwar, Zian H. Tseng, Christina D. Fang, Randall J. Lee, Melvin M. Scheinman, Joshua D. Moss, Trisha F. Hue, Emily Lee, Henry H. Hsia, Jonathan W. Dukes, Rachel A. Gladstone, Gregory Nah, Byron K. Lee, Tomos E. Walters, Edward P. Gerstenfeld, Jeffrey E. Olgin, Kelsey Ogomori, Monica Tung, David G. Rosenthal, and Shannon M Fan
- Subjects
Double blind ,Randomized controlled trial ,law ,business.industry ,Physiology (medical) ,Anesthesia ,Medicine ,Cardiology and Cardiovascular Medicine ,business ,Placebo ,law.invention - Published
- 2021
6. A Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Alcohol to Assess Changes in Atrial Electrophysiology
- Author
-
Vasanth Vedantham, Gregory Nah, Vijay A. Ramchandani, Eric Vittinghoff, Zian H. Tseng, Shannon M Fan, Edward P. Gerstenfeld, Tomos E. Walters, Kelsey Ogomori, Gregory M. Marcus, Joshua D. Moss, Jeffrey E. Olgin, Byron K. Lee, Rachel A. Gladstone, Nitish Badhwar, Melvin M. Scheinman, Jonathan W. Dukes, Emily Lee, Trisha F. Hue, Christina D. Fang, Randall J. Lee, and Henry H. Hsia
- Subjects
medicine.medical_specialty ,Alcohol Drinking ,medicine.medical_treatment ,Placebo-controlled study ,Alcohol ,030204 cardiovascular system & hematology ,Alcohol exposure ,Article ,Double blind ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Double-Blind Method ,Heart Conduction System ,Internal medicine ,Atrial Fibrillation ,medicine ,Humans ,cardiovascular diseases ,030212 general & internal medicine ,Atrial electrophysiology ,Heart Atria ,skin and connective tissue diseases ,business.industry ,Atrial fibrillation ,Ablation ,medicine.disease ,Electrophysiology ,chemistry ,Pulmonary Veins ,cardiovascular system ,Cardiology ,Blood Alcohol Content ,sense organs ,Cardiac Electrophysiology ,business - Abstract
This study sought to identify acute changes in human atrial electrophysiology during alcohol exposure.The mechanism by which a discrete episode of atrial fibrillation (AF) occurs remains unknown. Alcohol appears to increase the risk for AF, providing an opportunity to study electrophysiologic effects that may render the heart prone to arrhythmia.In this randomized, double-blinded, placebo-controlled trial, intravenous alcohol titrated to 0.08% blood alcohol concentration was compared with a volume and osmolarity-matched, masked, placebo in patients undergoing AF ablation procedures. Right, left, and pulmonary vein atrial effective refractory periods (AERPs) and conduction times were measured pre- and post-infusion. Isoproterenol infusions and burst atrial pacing were used to assess AF inducibility.Of 100 participants (50 in each group), placebo recipients were more likely to be diabetic (22% vs. 4%; p = 0.007) and to have undergone a prior AF ablation (36% vs. 22%; p = 0.005). Pulmonary vein AERPs decreased an average of 12 ms (95% confidence interval: 1 to 22 ms; p = 0.026) in the alcohol group, with no change in the placebo group (p = 0.98). Whereas no statistically significant differences in continuously assessed AERPs were observed, the proportion of AERP sites tested that decreased with alcohol (median: 0.5; interquartile range: 0.6 to 0.6) was larger than with placebo (median: 0.4; interquartile range: 0.2 to 0.6; p = 0.0043). No statistically significant differences in conduction times or in the proportion with inducible AF were observed.Acute exposure to alcohol reduces AERP, particularly in the pulmonary veins. These data demonstrate a direct mechanistic link between alcohol, a common lifestyle exposure, and immediate proarrhythmic effects in human atria. (How Alcohol Induces Atrial Tachyarrhythmias Study [HOLIDAY]; NCT01996943).
- Published
- 2020
7. Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation
- Author
-
Mellanie True Hills, Mark J. Pletcher, Sean Joyce, Debbe McCall, Kelsey Ogomori, Jeffrey E. Olgin, Gregory M. Marcus, Tzu-Chun Chu, Jiabei Yang, Kathi Sigona, Gregory Nah, Xochitl Butcher, Kathleen Sciarappa, Vivian Yang, Shiffen Gettabecha, Madelaine Faulkner Modrow, Ida Sim, and Christopher H. Schmid
- Subjects
Adult ,Male ,medicine.medical_specialty ,Alcohol Drinking ,Paroxysmal atrial fibrillation ,Psychological intervention ,Patient Positioning ,Single-Case Studies as Topic ,law.invention ,Electrocardiography ,Wearable Electronic Devices ,Primary outcome ,Randomized controlled trial ,Quality of life ,law ,Caffeine ,Internal medicine ,Atrial Fibrillation ,medicine ,Humans ,Trial registration ,Exercise ,Original Investigation ,Aged ,Dehydration ,business.industry ,Atrial fibrillation ,Feeding Behavior ,Middle Aged ,medicine.disease ,Cold Temperature ,Relative risk ,Quality of Life ,Female ,Self Report ,Smartphone ,Sleep ,Cardiology and Cardiovascular Medicine ,business - Abstract
IMPORTANCE: Atrial fibrillation (AF) is the most common arrhythmia. Although patients have reported that various exposures determine when and if an AF event will occur, a prospective evaluation of patient-selected triggers has not been conducted, and the utility of characterizing presumed AF-related triggers for individual patients remains unknown. OBJECTIVE: To test the hypothesis that n-of-1 trials of self-selected AF triggers would enhance AF-related quality of life. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial lasting a minimum of 10 weeks tested a smartphone mobile application used by symptomatic patients with paroxysmal AF who owned a smartphone and were interested in testing a presumed AF trigger. Participants were screened between December 22, 2018, and March 29, 2020. INTERVENTIONS: n-of-1 Participants received instructions to expose or avoid self-selected triggers in random 1-week blocks for 6 weeks, and the probability their trigger influenced AF risk was then communicated. Controls monitored their AF over the same time period. MAIN OUTCOMES AND MEASURES: AF was assessed daily by self-report and using a smartphone-based electrocardiogram recording device. The primary outcome comparing n-of-1 and control groups was the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) score at 10 weeks. All participants could subsequently opt for additional trigger testing. RESULTS: Of 446 participants who initiated (mean [SD] age, 58 [14] years; 289 men [58%]; 461 White [92%]), 320 (72%) completed all study activities. Self-selected triggers included caffeine (n = 53), alcohol (n = 43), reduced sleep (n = 31), exercise (n = 30), lying on left side (n = 17), dehydration (n = 10), large meals (n = 7), cold food or drink (n = 5), specific diets (n = 6), and other customized triggers (n = 4). No significant differences in AFEQT scores were observed between the n-of-1 vs AF monitoring-only groups. In the 4-week postintervention follow-up period, significantly fewer daily AF episodes were reported after trigger testing compared with controls over the same time period (adjusted relative risk, 0.60; 95% CI, 0.43- 0.83; P
- Published
- 2022
8. Prospective arrhythmia surveillance after a COVID-19 diagnosis
- Author
-
Thomas A Dewland, Isaac R Whitman, Sithu Win, Jose M Sanchez, Jeffrey E Olgin, Mark J Pletcher, Lekshmi Santhosh, Uday Kumar, Sean Joyce, Vivian Yang, Janet Hwang, Kelsey Ogomori, Noah Peyser, Cathy Horner, David Wen, Xochitl Butcher, and Gregory M Marcus
- Subjects
Adult ,Male ,Arrhythmias ,Cardiovascular ,Global Health ,Electrocardiography ,Clinical Research ,Ambulatory ,Diseases of the circulatory (Cardiovascular) system ,Humans ,Prospective Studies ,cardiovascular diseases ,Arrhythmias and Sudden Death ,Pandemics ,SARS-CoV-2 ,Incidence ,COVID-19 ,Arrhythmias, Cardiac ,electrophysiology ,Heart Disease ,Good Health and Well Being ,RC666-701 ,Population Surveillance ,Electrocardiography, Ambulatory ,cardiovascular system ,Female ,Cardiology and Cardiovascular Medicine ,Cardiac ,arrhythmias - Abstract
BackgroundCardiac arrhythmias have been observed among patients hospitalised with acute COVID-19 infection, and palpitations remain a common symptom among the much larger outpatient population of COVID-19 survivors in the convalescent stage of the disease.ObjectiveTo determine arrhythmia prevalence among outpatients after a COVID-19 diagnosis.MethodsAdults with a positive COVID-19 test and without a history of arrhythmia were prospectively evaluated with 14-day ambulatory electrocardiographic monitoring. Participants were instructed to trigger the monitor for palpitations.ResultsA total of 51 individuals (mean age 42±11 years, 65% women) underwent monitoring at a median 75 (IQR 34–126) days after a positive COVID-19 test. Median monitoring duration was 13.2 (IQR 10.5–13.8) days. No participant demonstrated atrial fibrillation, atrial flutter, sustained supraventricular tachycardia (SVT), sustained ventricular tachycardia or infranodal atrioventricular block. Nearly all participants (96%) had an ectopic burden of ConclusionsWe did not find evidence of malignant or sustained arrhythmias in outpatients after a positive COVID-19 diagnosis. While palpitations were common, symptoms frequently corresponded to sinus rhythm/sinus tachycardia or non-malignant arrhythmias such as isolated ectopy or non-sustained SVT. While these findings cannot exclude the possibility of serious arrhythmias in select individuals, they do not support a strong or widespread proarrhythmic effect of COVID-19 infection after resolution of acute illness.
- Published
- 2022
9. The Efficiency of Verteporfin as a Therapeutic Option in Pre-Clinical Models of Melanoma
- Author
-
Jon E. Hammarstedt, Jason W. Lui, Sixia Xiao, Kelsey Ogomori, Elizabeth C. Little, and Deborah Lang
- Subjects
0301 basic medicine ,Hippo signaling pathway ,business.industry ,Melanoma ,Cell ,Tumor initiation ,Macular degeneration ,medicine.disease ,Verteporfin ,eye diseases ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Oncology ,Cell culture ,030220 oncology & carcinogenesis ,medicine ,Cancer research ,business ,Transcription factor ,medicine.drug - Abstract
Yes Associated Protein 1 (YAP) and Transcriptional coactivator with PDZ-Binding Motif (TAZ) have gained notoriety for their ability to drive tumor initiation and progression in a wide variety of cancers, including melanoma. YAP and TAZ act as drivers of melanoma through its interaction with the TEAD family of transcription factors. Verteporfin is a benzoporphyrin derivative that is used clinically for photodynamic treatment of macular degeneration. Recently it has emerged as a potential inhibitor of YAP/TAZ-TEAD interaction independent of light activation. In this study we determine if verteporfin has clinical potential by testing this compound on human melanoma cell cultures and in a clinically significant mouse model, BrafCA; Tyr-CreERT2; Ptenf/f, which parallels human melanoma in terms of disease progression, genetics, and histopathology. In culture, Verteporfin treatment induces a rapid drop in YAP and TAZ protein levels and cell numbers. In the transgenic model, utilizing drug levels that correspond to previously determined safe doses in human patients and with a dosing regimen calculated in this study, Verteporfin did not inhibit melanoma initiation or progression in comparison to mock treated controls. Taken together, our study suggests that although Verteporfin induces YAP/TAZ degradation in melanoma cell lines, Verteporfin was not effective as a YAP/TAZ-TEAD specific inhibitor of melanoma in our studies that aimed to mimic conditions found in clinic in terms of treatment regimen and disease model.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.